{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-007788","form_type":"8-K","ticker":"CMPS","cik":"0001816590","company_name":"COMPASS Pathways plc","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.654770+00:00","generated_at":"2026-06-05T07:13:56.765441+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Compass Pathways Q4 2023 net loss $32.5M; COMP005 data delayed to Q4 2024","bullets":["Net loss for FY2023 $118.5M ($2.32/sh) vs $91.5M ($2.16/sh) in 2022.","Cash $220.2M at Dec 31, 2023; raised additional $31.4M net in Q1 2024.","COMP005 phase 3 top-line data delayed to Q4 2024; COMP006 still on track for mid-2025.","Teri Loxam appointed CFO effective March 1, 2024.","FY2024 net cash used in operations expected $110-130M; runway into late 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-007788","json":"https://secwatch.observer/filing/0001628280-24-007788.json","markdown":"https://secwatch.observer/filing/0001628280-24-007788.md","text":"https://secwatch.observer/filing/0001628280-24-007788.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816590/000162828024007788/0001628280-24-007788-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816590/000162828024007788/cmps-20240229.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T07:13:56.765441+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"22b04fe840306dc8c95f7e733e0879bb2d60f39d","claim":"COMPASS Pathways plc reported fourth quarter and year ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023, was $118.5 million, or $2.32 loss per share, EPS $2.32 loss per share.","evidence_excerpt":"Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter 2023 and provided an update on recent progress across its business.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1816590/000162828024007788/0001628280-24-007788-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and year ended December 31, 2023"},{"label":"Net income","value":"Net loss for the year ended December 31, 2023, was $118.5 million, or $2.32 loss per share"},{"label":"EPS","value":"$2.32 loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}